

CME Group Inc. (CME)

\$184.17 (As of 05/11/20)

Price Target (6-12 Months): **\$193.00**

Long Term: 6-12 Months

Zacks Recommendation:

Neutral

(Since: 06/05/19)

Prior Recommendation: Underperform

Short Term: 1-3 Months

Zacks Rank: (1-5)

2-Buy

Zacks Style Scores:

VGM:F

Value: D

Growth: C

Momentum: F

Summary

CME Group remains well-poised for growth on strong market position driven by varied derivative product lines. Efforts to expand and cross sell through strategic alliances, acquisitions, new product initiatives and a stable global presence bode well. Product innovation and growing proportion of volume from customers outside the United States have been aiding results. Its shares have underperformed its industry in a year. However, escalating expenses are likely to put pressure on margin expansion. Its diversified product portfolio is significantly exposed to volatile interest rate, firm government regulations and limited credit availability in unstable capital and credit market. CME Group's first-quarter earnings per share of \$2.33 beat the Zacks Consensus Estimate by 4.5% and improved 43.8% year over year.


Price, Consensus & Surprise



Data Overview

52 Week High-Low	\$225.36 - \$131.80
20 Day Average Volume (sh)	1,916,089
Market Cap	\$66.0 B
YTD Price Change	-8.3%
Beta	0.32
Dividend / Div Yld	\$3.40 / 1.8%
Industry	Securities and Exchanges
Zacks Industry Rank	Top 7% (18 out of 253)

Sales and EPS Growth Rates (Y/Y %)



Last EPS Surprise	4.5%
Last Sales Surprise	1.4%
EPS F1 Est- 4 week change	0.1%
Expected Report Date	07/29/2020
Earnings ESP	-0.8%
P/E TTM	24.5
P/E F1	23.8
PEG F1	3.6
P/S TTM	12.7

Sales Estimates (millions of \$)

	Q1	Q2	Q3	Q4	Annual*
2021	1,352 E	1,367 E	1,375 E	1,350 E	5,259 E
2020	1,522 A	1,310 E	1,307 E	1,246 E	5,380 E
2019	1,180 A	1,273 A	1,277 A	1,138 A	4,868 A

EPS Estimates

	Q1	Q2	Q3	Q4	Annual*
2021	\$2.02 E	\$1.96 E	\$1.98 E	\$1.83 E	\$7.50 E
2020	\$2.33 A	\$1.85 E	\$1.83 E	\$1.75 E	\$7.75 E
2019	\$1.62 A	\$1.76 A	\$1.90 A	\$1.52 A	\$6.80 A

*Quarterly figures may not add up to annual.

The data in the charts and tables, including the Zacks Consensus EPS and Sales estimates, is as of 05/11/2020. The reports text is as of 05/12/2020.


Overview

Formed in 2007 by the merger of the Chicago Mercantile Exchange (CME) and the Chicago Board of Trade (CBOT), CME Group is the largest futures exchange in the world in terms of trading volume as well as notional value traded. The Chicago Mercantile Exchange was originally formed as a non-profit organization in 1898, but was converted to a for-profit company in 2000. It became the first publicly traded financial exchange in the U.S. in Dec 2002. CBOT, established in 1848, is a leading futures and options exchange. In Apr 2005, CBOT converted into a for-profit stock-based holding company and for-profit membership exchange subsidiary.

CME Group offers a broad range of products covering major asset classes, based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities and metals. Trades are executed through CME Group's electronic trading platforms, open outcry and privately negotiated transactions. CME Group also operates one of the world's leading central counterparty clearing providers through CME Clearing and CME Clearing Europe, which offer clearing and settlement services across asset classes for exchange-traded and over-the-counter derivatives.

Apart from CME and CBOT, the company operates New York Mercantile Exchange, Inc. (NYMEX) and Commodity Exchange, Inc. (COMEX), CME Clearing Europe Limited (CMECE) and CME Europe Limited (CME Europe). The company reports the results of its operations as one operating segment mainly comprised of CME, CBOT, NYMEX and COMEX.

CME Group's 81.1% revenues were derived from clearing and transaction fees in 2019. These fees include electronic trading fees, surcharges for privately negotiated transactions and other volume-related charges for exchange-traded and cleared swaps contracts. The company's product line includes **Interest-rate** trading, **Energy and Equity** trading contracts, **Foreign exchange**, **Agricultural commodities** and **Metal**.



Reasons To Buy:

- ▲ Shares of the company have gained 1% in a year, against the industry's growth of 15.2%. Nevertheless, its solid fundamentals are likely to drive shares in the days ahead.
- ▲ Organic growth has been CME Group's key strength as reflected in its revenue growth story. Revenues witnessed a CAGR of nearly 10% over the last five years (2015-2019). The top line also improved 29% in first-quarter 2020, courtesy of higher clearing and transaction fees (up 34.2% year over year), market data and information services (up 1.1%) and other revenues (up 15.4%). Also, we believe that the company should retain its revenue momentum in the coming quarters, given its sturdy market position with diverse derivative product lines and global reach. Growth was witnessed globally. Increasing electronic trading volume adds scalability and hence leverage to CME Group's operating model.
- ▲ Fundamental growth remains a huge driver for the company's improving operating leverage, through which CME group leads with about 90% market share of the global futures trading and clearing services. In addition to the expansion of futures products in emerging markets, non-transaction related opportunities and over the counter (OTC) offerings should continue to contribute to top-line growth. Its options business too gained traction. The company also notes structural shifts in both the crude and natural gas markets as the U.S. is now becoming the swing producer in these markets and thus expects to capitalize on and benefit from this shift. However, the COVID-19 pandemic is putting the global oil market under pressure, which is already grappling with declining demand and oversupply issues.
- ▲ CME Group continuously weighs on strategic initiatives that will accelerate its growth. While in 2018 it shut down London-based derivatives exchange and clearing house, CME Europe and CME Clearing Europe to generate annual savings between \$10 million and \$12 million and free up over \$150 million in capital, it also exited credit default swap clearing business to focus on over-the-counter clearing services on interest rate swaps and foreign exchange. Since its acquired unit NEX Exchange has been incurring losses, the decision of divesting the unit to Aquis Exchange plc also bodes well.
- ▲ The company remains focused on making investments, which will make it convenient for clients to trade complex spread options on the box electronically. Currently, the company remains focused on investments in several areas, including organic market data growth and new product extensions and offerings. CME Group continues to maintain a solid liquidity position, with cash and cash equivalents amounting to \$851.7 as of Mar 31, 2020. The company holds a strong debt profile with no maturities until 2022. It has achieved its target of 1X debt-to-EBITDA in the first quarter only, which it had aimed to achieve by 2020 end. Notably, the company's long-term debt came in at \$3.5 billion in the first quarter, which declined 5.4% from the 2019-end level. As of Mar 31, 2020, the company's total debt/ total capital of 11.7% is lower than its figure of 12.5% at 2019-end. Further, the company's times interest earned of 18.8 as on Mar 31, 2020 is good when compared with the 2019-end figure of 16.1, implying that its earnings are sufficient to cover interest obligations.
- ▲ Modest liquidity supports healthy capital deployment via dividend payouts, thereby adding to the company's financial flexibility and investor confidence. CME Group pays five dividends per year with the fifth being variable, which is based on excess cash flow in the year. Since it commenced the variable dividend policy in early 2012, CME Group has returned more than \$12 billion in quarterly and variable dividends to its shareholders. On Feb 5, 2020, the company raised its quarterly dividend by 13% to 85 cents per share from the prior payout of 75 cents. Its dividend yield of 1.8% is better than the industry average of 1.5%, making the stock an attractive pick for yield-seeking investors.
- ▲ Most of CME Group's long-term growth investments made in the past are showing desirable upsides. In September 2017, CME Group announced launch of CME FX link, enabling investors to trade on Globex. CME Group continues to launch products to address diverse needs of its customers. In September 2018, the company introduced a new interactive CME Liquidity Tool, allowing the market participants to make an analysis of liquidity, book depth and cost to trade statistics across the CME asset classes. This new tool has already garnered interest from clients worldwide. Also, the company mentioned the extension of the exclusive NASDAQ futures license through 2029, which will provide a seamless access to the NASDAQ product suite to its clients.

Efforts to expand futures products in emerging markets, non-transaction related opportunities, OTC offerings, cross-sell through alliances, strong global presence, solid liquidity should drive growth.

Reasons To Sell:

- ▼ CME Group's diversified product portfolio is significantly exposed to extreme interest rate volatility, currency fluctuation, firm government regulations and limited credit availability in the current unstable capital and credit markets, which can hamper liquidity and cause a decline in the customer demand lest this trade scenario continues or worsens in the future. Furthermore, a low interest rate environment in the United States as well as the COVID-19 pandemic is adding to the insurer's woes as it is likely to keep margins under pressure. Although the company has diversified its product array, it is still immensely dependent on trading volumes from two product lines for a significant portion of its clearing and transaction fee revenues, which poses concentration risk.
- ▼ Escalating total expenses remain a major concern for CME Group. Expenses have increased in the past few quarters mainly due to higher compensation and benefits, technology expenses, professional fees and outside services, licensing and other fee agreements, depreciation and amortization, and other. The momentum continued in the first quarter of 2020, with the metric rising 2.5% in first-quarter 2020. For 2020, CME Group expects operating expenses excluding license fees in the range of \$1.64-\$1.65 billion.
- ▼ Finally, the barriers to entry in electronic trading are much lower than in open-outcry markets and create intense competition, which has been affecting both volume and pricing at CME Group. The ongoing consolidation in the industry has raised caution over the sustainability factor of the sturdy groups and poses an uphill task to gain market share. The new clearing house from LME is further likely to heighten competition in the UK. CME Europe is also facing stiff competition from Eurex Exchange in FX trading. Therefore, the company requires aggressive measures to sustain the dynamically changing industry trends.

The ongoing weakness in derivative markets, escalating costs, exposure to interest rate volatility, currency fluctuation and intense competition remain key concerns for CME Group.

Last Earnings Report

CME Group's Q1 Earnings Top Estimates, Revenues Up Y/Y

CME Group reported first-quarter 2020 adjusted earnings per share of \$2.33, which surpassed the Zacks Consensus Estimate by 4.5%. The bottom line also improved 43.8% year over year, primarily due to higher revenues.

Performance in Detail

CME Group's revenues of \$1.5 billion increased 29% year over year courtesy of strong clearing and transaction fees. Moreover, the top line beat the Zacks Consensus Estimate by 1.4%. The year-over-year improvement in revenues can be attributed to higher clearing and transaction fees, which improved 34.2% year over year.

Total expenses increased 2.5% year over year to \$562.2 million during the reported quarter on account of higher professional fees and outside services; depreciation and amortization; licensing and other fee agreements plus other expenses.

Operating income improved 52.1% from the prior-year quarter to \$959.9 million.

Average daily volume surged 45% year over year to 27 million contracts in the quarter.

Financial Update

As of Mar 31, 2020, CME Group had \$851.7 million of cash and cash equivalents, down 45.1% from the level at 2019 end. As of Mar 31, 2020, long-term debt of \$3.5 billion slipped 5.4% from the figure at 2019 end.

The company exited the first quarter with total assets worth \$137.9 billion, up 83.4% from the number at 2019 end.

Capital Deployment

CME Group announced dividends of \$1.2 billion for the first quarter including the annual variable dividend worth \$894 million. The company returned \$13.5 billion to its shareholders via since the implementation of the variable dividend policy in early 2012.

Quarter Ending 03/2020

Report Date	Apr 29, 2020
Sales Surprise	1.37%
EPS Surprise	4.48%
Quarterly EPS	2.33
Annual EPS (TTM)	7.51

Recent News

CME Group Declares Quarterly Dividend — May 6, 2020

The board of directors of Group recently declared a second-quarter dividend of 85 cents per share. The dividend will be paid out on Jun 25 to shareholders of record as of Jun 10.

CME Group Reports Monthly Volume for April 2020 – May 4, 2020

CME Group reported average daily volume (ADV) for April 2020. Volumes increased 13% year over year to 17.8 million contracts during the month. Interest Rate options ADV came in at 6.8 million contracts. Equity Indexes ADV of 5.1 million contracts increased 119% year over year. Metals ADV increased 15% to 505,000 contracts and Energy ADV of 3.4 million contracts increased 39%.

Valuation

CME Group's shares are down 8.3% and up 1% in the year-to-date period and over the trailing 12-month period, respectively. Stocks in the Zacks sub-industry and the Zacks Finance sector are up 0.4% and down 26.4% in the year-to-date period, respectively. Over the past year, the Zacks sub-industry and sector are up 15.2% and down 18.9%, respectively.

The S&P 500 index is down 9.1% in the year-to-date period and 3.9% in the past year.

The stock is currently trading at 24.04x forward 12-month earnings, which compares to 24.06x for the Zacks sub-industry, 15.15x for the Zacks sector and 21.15x for the S&P 500 index.

Over the past five years, the stock has traded as high as 31.23x and as low as 18.24x, with a 5-year median of 24.31x. Our Neutral recommendation indicates that the stock will perform in-line with the market. Our \$193 price target reflects 25.19x earnings.

The table below shows summary valuation data for CME

Valuation Multiples - CME					
		Stock	Sub-Industry	Sector	S&P 500
P/E F12M	Current	24.04	24.06	15.15	21.15
	5-Year High	31.23	27.47	16.18	21.15
	5-Year Low	18.24	18.49	11.58	15.19
	5-Year Median	24.31	21.89	13.94	17.45
P/S F12M	Current	12.37	11.47	5.81	3.3
	5-Year High	16.63	12.94	6.7	3.44
	5-Year Low	7.7	7.27	4.99	2.54
	5-Year Median	11.86	10.16	6.05	3.02
P/B TTM	Current	2.48	3.23	2.08	3.85
	5-Year High	3.06	3.54	2.90	4.55
	5-Year Low	1.34	1.81	1.71	2.84
	5-Year Median	2.23	2.63	2.53	3.65

As of 05/11/2020

Industry Analysis Zacks Industry Rank: Top 7% (18 out of 253)



Top Peers

Company (Ticker)	Rec	Rank
MarketAxess Holdings Inc (MKTX)	Outperform	1
Cboe Global Markets Inc (CBOE)	Neutral	2
Investment Company of America (ICA)	Neutral	3
Intercontinental Exchange Inc (ICE)	Neutral	2
Moodys Corporation (MCO)	Neutral	3
MSCI Inc (MSCI)	Neutral	3
Nasdaq Inc (NDAQ)	Neutral	3
OTC Markets Group Inc (OTCM)	Neutral	4

Industry Comparison Industry: Securities And Exchanges				Industry Peers		
	CME	X Industry	S&P 500	CBOE	ICE	NDAQ
Zacks Recommendation (Long Term)	Neutral	-	-	Neutral	Neutral	Neutral
Zacks Rank (Short Term)	2	-	-	2	2	3
VGM Score	F	-	-	C	C	C
Market Cap	66.01 B	19.15 B	19.55 B	10.96 B	51.49 B	17.92 B
# of Analysts	7	7	14	7	7	7
Dividend Yield	1.85%	1.44%	2.13%	1.44%	1.28%	1.72%
Value Score	D	-	-	D	D	D
Cash/Price	0.01	0.03	0.06	0.02	0.03	0.07
EV/EBITDA	20.54	16.17	11.85	16.17	16.17	14.93
PEG Ratio	3.60	2.58	2.60	7.25	2.58	2.23
Price/Book (P/B)	2.48	3.32	2.71	3.31	3.04	3.32
Price/Cash Flow (P/CF)	22.64	18.35	10.71	15.41	18.35	17.55
P/E (F1)	23.76	20.96	19.55	18.85	20.96	19.65
Price/Sales (P/S)	12.67	7.27	2.01	3.89	7.27	3.92
Earnings Yield	4.21%	4.77%	4.85%	5.31%	4.77%	5.09%
Debt/Equity	0.13	0.30	0.76	0.30	0.33	0.61
Cash Flow (\$/share)	8.13	6.22	7.01	6.48	5.13	6.22
Growth Score	C	-	-	B	C	C
Hist. EPS Growth (3-5 yrs)	16.67%	13.38%	10.82%	22.89%	13.38%	11.36%
Proj. EPS Growth (F1/F0)	13.99%	13.87%	-9.99%	11.99%	15.69%	11.20%
Curr. Cash Flow Growth	12.13%	5.26%	5.83%	-6.75%	7.25%	0.39%
Hist. Cash Flow Growth (3-5 yrs)	16.24%	18.37%	8.52%	25.08%	15.62%	10.02%
Current Ratio	1.01	1.02	1.27	1.77	0.99	0.97
Debt/Capital	11.74%	23.14%	44.41%	23.14%	24.89%	37.74%
Net Margin	45.79%	29.65%	10.59%	15.49%	29.65%	15.94%
Return on Equity	10.15%	17.64%	16.36%	17.64%	13.85%	16.08%
Sales/Assets	0.06	0.33	0.55	0.55	0.07	0.33
Proj. Sales Growth (F1/F0)	10.52%	10.05%	-2.41%	10.79%	10.05%	6.26%
Momentum Score	F	-	-	F	B	B
Daily Price Chg	1.45%	0.72%	-0.95%	-0.30%	0.62%	1.53%
1 Week Price Chg	4.54%	5.47%	3.23%	6.56%	5.47%	0.91%
4 Week Price Chg	0.82%	7.04%	4.49%	7.04%	10.47%	5.76%
12 Week Price Chg	-13.59%	-5.99%	-20.09%	-20.50%	-2.85%	-5.99%
52 Week Price Chg	1.03%	16.86%	-7.00%	-3.16%	16.86%	20.18%
20 Day Average Volume	1,916,089	875,275	2,530,553	929,058	2,791,229	875,275
(F1) EPS Est 1 week change	0.00%	0.00%	0.00%	0.52%	0.00%	0.00%
(F1) EPS Est 4 week change	0.15%	0.15%	-6.07%	1.48%	2.01%	0.10%
(F1) EPS Est 12 week change	5.56%	5.56%	-15.69%	8.58%	7.57%	1.99%
(Q1) EPS Est Mthly Chg	-1.33%	0.15%	-12.45%	-1.84%	1.64%	1.83%

Zacks Stock Rating System

We offer two rating systems that take into account investors' holding horizons: Zacks Rank and Zacks Recommendation. Each provides valuable insights into the future profitability of the stock and can be used separately or in combination with each other depending on your investment style.

Zacks Recommendation

The Zacks Recommendation aims to predict performance over the next 6 to 12 months. The foundation for the quantitatively determined Zacks Recommendation is trends in the company's estimate revisions and earnings outlook. The Zacks Recommendation is broken down into 3 Levels; Outperform, Neutral and Underperform. Unlike many Wall Street firms, we have an excellent balance between the number of Outperform and Neutral recommendations. Our team of 70 analysts are fully versed in the benefits of earnings estimate revisions and how that is harnessed through the Zacks quantitative rating system. But we have given our analysts the ability to override the Zacks Recommendation for the 1200 stocks that they follow. The reason for the analyst over-rides is that there are often factors such as valuation, industry conditions and management effectiveness that a trained investment professional can spot better than a quantitative model.

Zacks Rank

The Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon. The underlying driver for the quantitatively-determined Zacks Rank is the same as the Zacks Recommendation, and reflects trends in earnings estimate revisions.

Zacks Style Scores

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

Value Score	D
Growth Score	C
Momentum Score	F
VGM Score	F

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

Disclosures

This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock. The EPS and revenue forecasts are the Zacks Consensus estimates, unless indicated otherwise on the reports first page. Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment. This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. ZIR is not a broker-dealer. ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients. Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.

No part of this report can be reprinted, republished or transmitted electronically without the prior written authorization of ZIR.